[Surfactant treatment of newborn infants receiving continuous positive airway pressure treatment].

Abstract

INTRODUCTION:

The purpose of this study was to examine the efficiency of a single dose of fast-acting exogenous surfactant (Curosurf) given to premature babies with progressive respiratory insufficiency. Curosurf was given as early rescue therapy during a brief intubation (INSURE method: INtubation-SURfactant-Extubation) during treatment with nasal Continuous Positive Airway Pressure (CPAP).

MATERIALS AND METHODS:

Retrospective study of 115 premature infants with respiratory distress syndrome born and treated at Odense University Hospital during the years 1999 to 2004. The criterion for surfactant treatment was a decrease in the arterial/alveolar oxygen tension ratio (or corresponding values for the fraction of inspired oxygen) below 0.36 in infants with gestational age (GA) < 30 weeks and 0.22 in more mature infants.

RESULTS:

The primary end point was survival during the first week of life without mechanical ventilation. This end point was reached by 51% of the infants with GA < 30 weeks. However, the effect proved to be GA-dependent, increasing from 22% in infants with a GA of 24-25 weeks to 86% in week 29. Seventy percent survived to be discharged. In infants with GA > 29 weeks the effect was 87%, and all survived.

CONCLUSION:

The effect of surfactant therapy administered per the INSURE method is GA-dependent, and the method works best after GA week 25. The question is whether earlier therapy will increase its efficiency or the method has reached its limit.

• Authors: Tina Andersen, Hanne Spangsberg Holm, Jens Kamper
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 168 Issue 43 Pg. 3723-7 (Oct 23 2006) ISSN: 1603-6824 [Electronic] Denmark
• Vernacular Title: Surfaktantbehandling af nyfødte børn i continuous positive airway pressure-behandling.
• PMID: 17069738 (Publication Type: English Abstract, Journal Article)

Chemical References

• Biological Products
• Phospholipids
• Pulmonary Surfactants
• poractant alfa

Topics

• Biological Products (administration & dosage)
• Continuous Positive Airway Pressure
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Premature
• Phospholipids (administration & dosage)
• Pulmonary Surfactants (administration & dosage)
• Respiratory Distress Syndrome, Newborn (drug therapy, therapy)
• Retrospective Studies
• Treatment Outcome